A Randomized, Open-label Study to Evaluate the Efficacy and Safety of KN057 Injection Prophylaxis in Patients With Hemophilia A or B Without Inhibitors
Latest Information Update: 26 Aug 2024
Price :
$35 *
At a glance
- Drugs KN 057 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Sponsors Alphamab Oncology
- 26 Aug 2024 New trial record